BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15063971)

  • 1. Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.
    Morice P; Pautier P; Delaloge S; Spatz A; Chompret A
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):251-4. PubMed ID: 15063971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laparoscopic prophylactic oophorectomy plus N3 lymphadenectomy for advanced rectosigmoid cancer.
    Liang JT; Lai HS; Wu CT; Huang KC; Lee PH; Shun CT
    Ann Surg Oncol; 2007 Jul; 14(7):1991-9. PubMed ID: 17447107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
    Ayhan A; Guvenal T; Salman MC; Ozyuncu O; Sakinci M; Basaran M
    Gynecol Oncol; 2005 Aug; 98(2):235-41. PubMed ID: 15982725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
    Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
    Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
    Kauff ND; Barakat RR
    J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pelvic lymphadenectomy as an alternative to adjuvant radiotherapy in early stage endometrial cancer at high risk of recurrent lymphatic metastases (stage I)].
    Amato NA; Partipilo V; Mele F; Boscia F; De Marzo P
    Minerva Ginecol; 2009 Feb; 61(1):1-12. PubMed ID: 19204656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families.
    Evans DG; Young K; Bulman M; Shenton A; Wallace A; Lalloo F
    Clin Genet; 2008 Apr; 73(4):338-45. PubMed ID: 18312450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
    Aletti GD; Dowdy S; Podratz KC; Cliby WA
    Am J Obstet Gynecol; 2006 Dec; 195(6):1862-8. PubMed ID: 17132488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
    Roger N; Zafrani Y; Uzan C; Gouy S; Rey A; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
    Ann Surg Oncol; 2008 Jan; 15(1):333-8. PubMed ID: 17943386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review].
    Fruscalzo A; Lellé RJ; Calcagno A; Driul L; Damante G; Marchesoni D
    Minerva Ginecol; 2006 Apr; 58(2):171-5. PubMed ID: 16582871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.
    Eitan R; Soslow R; Lin O; Kauff ND; Liu L; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Aug; 102(2):315-8. PubMed ID: 16430946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
    Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
    J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives.
    Egeli U; Cecener G; Tunca B; Tasdelen I
    Cancer Invest; 2006; 24(5):484-91. PubMed ID: 16939956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
    Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
    Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.